medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-144-149medsovet-5318Research ArticleОнкогинекологияOncogynecologyПрактические аспекты лечения рецидивов BRCA-ассоциированного рака яичниковPractical aspects of treating relapsed BRCA-associated ovarian cancerhttps://orcid.org/0000-0003-4443-9974РумянцевА. А.RumyantseA. A.

врач-онколог онкологического отделения лекарственных методов лечения (химиотерапевтического) №2

115478, Россия, Москва, Каширское шоссе, д. 24

Oncologist, Cancer Drug Therapy (Chemotherapeutic) Department No 2

24 Kashirskoe shosse, Moscow, 115478, Russia

alexeymma@gmail.comhttps://orcid.org/0000-0002-6104-7473ТюляндинаА. С.TyulyandinaA. S.

старший научный сотрудник отделения лекарственных методов лечения (химиотерапевтического) №2

115478, Россия, Москва, Каширское шоссе, д. 24

Senior Researcher, Cancer Drug Therapy (Chemotherapeutic) Department No. 2

 24 Kashirskoe shosse, Moscow, 115478, Russia

atjulandina@mail.ruНаучно-исследовательский институт клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии имени Н.Н. БлохинаРоссияN. N. Trapeznikov Research Institute of Clinical Oncology, Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationRussian Federation201907122019019144149Copyright © Румянцев А.А., Тюляндина А.С., 20192019Румянцев А.А., Тюляндина А.С.Rumyantse A.A., Tyulyandina A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5318олапарибрак яичниковхимиотерапияBRCAрецидив рака яичниковплатиновые препаратыolaparibovarian cancerchemotherapyBRCArelapsed ovarian cancerplatinum drugsReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 250 c. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf. Последний доступ 08.10.2019.Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). Cancer statistics in Russia in 2018. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2019. 250 с. (In Russ.) Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf. Last accessed: 08.10.2019.Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf. Последний доступ: 05.10.2019.Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). Current status of cancer treatment in Russia, 2018. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2019. 236 с. (In Russ.) Available at: http://www.oncology.ru/service/statistics/condition/2018.pdf. Last accessed: 05.10.2019.Stratton J.F., Pharoah P., Smith S.K., Easton D., Ponder B.A.J. A systematic review and metaanalysis of family history and risk of ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 1998;105(5):493-499. doi: 10.1111/j.1471-0528.1998.tb10148.x.Stratton J.F., Pharoah P., Smith S.K., Easton D., Ponder B.A.J. A systematic review and metaanalysis of family history and risk of ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 1998;105(5):493-499. doi: 10.1111/j.1471-0528.1998.tb10148.x.Tyulyandina A., Gorbunova V., Khokhlova S., et al. Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study. AACR Annual Meeting. 2018; April 14-18, 2018. doi: 10.1158/1538-7445.AM2018-1241.Tyulyandina A., Gorbunova V., Khokhlova S., et al. Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study. AACR Annual Meeting. 2018; April 14-18, 2018. doi: 10.1158/1538-7445.AM2018-1241.Soegaard M., Kjaer S.K., Cox M., et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research. 2008;14(12):3761-3767. doi: 10.1158/1078-0432.CCR-07-4806.Soegaard M., Kjaer S.K., Cox M., et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research. 2008;14(12):3761-3767. doi: 10.1158/1078-0432.CCR-07-4806.George A., Kaye S., Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature Reviews Clinical Oncology. 2017;14(5):284-296. doi: 10.1038/nrclinonc.2016.191.George A., Kaye S., Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature Reviews Clinical Oncology. 2017;14(5):284-296. doi: 10.1038/nrclinonc.2016.191.Møller P., Hagen A.I., Apold J., et al. Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers. European Journal of Cancer. 2007;43(11):1713-1717. doi: 10.1016/j.ejca.2007.04.023Møller P., Hagen A.I., Apold J., et al. Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers. European Journal of Cancer. 2007;43(11):1713-1717. doi: 10.1016/j.ejca.2007.04.023Alsop K., Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30(21):2654-2663. doi: 10.1200/JCO.2011.39.8545.Alsop K., Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30(21):2654-2663. doi: 10.1200/JCO.2011.39.8545.Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations. Clin Cancer Res. 2002;8(12):3776-3781.Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations. Clin Cancer Res. 2002;8(12):3776-3781.Yun M.H., Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochemical Society Transactions. 2009;37(3):597-604. doi: 10.1042/BST0370597.Yun M.H., Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochemical Society Transactions. 2009;37(3):597-604. doi: 10.1042/BST0370597.Ashworth A. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. Journal of Clinical Oncology. 2008;26(22):3785-3790. doi: 10.1200/JCO.2008.16.0812.Ashworth A. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. Journal of Clinical Oncology. 2008;26(22):3785-3790. doi: 10.1200/JCO.2008.16.0812.Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discovery. 2015;5(11):1137-1154. doi: 10.1158/2159-8290.CD-15-0714.Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discovery. 2015;5(11):1137-1154. doi: 10.1158/2159-8290.CD-15-0714.Mirza M.R., Monk B.J., Herrstedt J., et al. Niraparib Maintenance Therapy in PlatinumSensitive, Recurrent Ovarian Cancer. New England Journal of Medicine. 2016;375(22):2154-2164. doi: 10.1056/NEJMoa1611310.Mirza M.R., Monk B.J., Herrstedt J., et al. Niraparib Maintenance Therapy in PlatinumSensitive, Recurrent Ovarian Cancer. New England Journal of Medicine. 2016;375(22):2154-2164. doi: 10.1056/NEJMoa1611310.Coleman R.L., Oza A.M., Lorusso D., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6.Coleman R.L., Oza A.M., Lorusso D., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6.Pujade-Lauraine E., Ledermann J.A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-сontrolled, phase 3 trial. The Lancet Oncology. 2017;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2.Pujade-Lauraine E., Ledermann J.A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-сontrolled, phase 3 trial. The Lancet Oncology. 2017;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2.Ledermann J., Harter P., Gourley C., et al. Olaparib Maintenance Therapy in PlatinumSensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 2012;366(15):1382-1392. doi:10.1056/NEJMoa1105535.Ledermann J., Harter P., Gourley C., et al. Olaparib Maintenance Therapy in PlatinumSensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 2012;366(15):1382-1392. doi: 10.1056/NEJMoa1105535.McNeish I.A., Ledermann J.A., Webber L., et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Annals of Oncology. 2014;25(10):1988-1995. doi: 10.1093/annonc/mdu363.McNeish I.A., Ledermann J.A., Webber L., et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Annals of Oncology. 2014;25(10):1988-1995. doi: 10.1093/annonc/mdu363.Ledermann J.A., Harter P., Gourley C., et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 2016;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X.Ledermann J.A., Harter P., Gourley C., et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 2016;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X.Friedlander M., Matulonis U., Gourley C., et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer. 2018;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y.Friedlander M., Matulonis U., Gourley C., et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer. 2018;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y.Ledermann J., Harter P, Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852-861. doi: 10.1016/S1470-2045(14)70228-1.Ledermann J., Harter P, Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852-861. doi: 10.1016/S1470-2045(14)70228-1.Любченко Л.Н., Батенева Е.И., Абрамов И.С. и соавт. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013;(2):53-61. doi: 10.18027/2224-5057-2013-2-53-61.Lyubchenko L.N., Bateneva E.I., Abramov I.S.et al. Hereditary breast and ovarian cancer. Zlokachestvennye opukholi = Malignant tumours. 2013;(2):53-61. (In Russ.) doi: 10.18027/2224-5057-2013-2-53-61.Plon S.E., Eccles D.M., Easton D., et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation. 2008;29(11):1282-1291. doi: 10.1002/humu.20880.Plon S.E., Eccles D.M., Easton D., et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation. 2008;29(11):1282-1291. doi: 10.1002/humu.20880.Kolor K., Chen Z., Grosse S.D., et al. BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas – United States, 2009–2014. MMWR Surveillance Summaries. 2017;66(15):1-11. doi: 10.15585/mmwr.ss6615a1.Kolor K., Chen Z., Grosse S.D., et al. BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas – United States, 2009–2014. MMWR Surveillance Summaries. 2017;66(15):1-11. doi: 10.15585/mmwr.ss6615a1.Cline M.S., Babbi G., Bonache S., et al. Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants. Human Mutation. 2019;40(9):1546-1556. doi: 10.1002/humu.23861.Cline M.S., Babbi G., Bonache S., et al. Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants. Human Mutation. 2019;40(9):1546-1556. doi: 10.1002/humu.23861.Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Journal of Clinical Oncology. 2002;20(6):1480-1490. doi: 10.1200/JCO.2002.20.6.1480.Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Journal of Clinical Oncology. 2002;20(6):1480-1490. doi: 10.1200/JCO.2002.20.6.1480.Gunderson C.C., Matulonis U., Moore K.N. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecologic Oncology. 2018;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010.Gunderson C.C., Matulonis U., Moore K.N. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecologic Oncology. 2018;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010.Friedlander M., Gebski V., Gibbs E., et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinumsensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. The Lancet Oncology. 2018;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7.Friedlander M., Gebski V., Gibbs E., et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinumsensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. The Lancet Oncology. 2018;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7.Robson M.E., Tung N., Conte P., et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. 2019;30(4):558-566. doi: 10.1093/annonc/mdz012Robson M.E., Tung N., Conte P., et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. 2019;30(4):558-566. doi: 10.1093/annonc/mdz012

The authors declare that there are no conflicts of interest present.